Links to sites outside of Lundbeck Canada are provided as resources to visitors and may not reflect Canada regulation or prescribing information. Lundbeck Canada accepts no responsibility for the content of linked sites.
March 20, 2020 – Like many organizations across the country and around the world, Lundbeck is closely monitoring the COVID-19 outbreak and its impact on our patients, communities and fiercely dedicated healthcare providers. Our utmost priority is to protect the well-being of the communities we serve and our Lundbeck colleagues nationwide, and so we are taking responsible action within our control to limit the rapid escalation of the virus and maintain support of our provider and patient communities.Lundbeck has an unwavering commitment to improving the lives of people affected by brain diseases, and we understand the compounded challenges that people living with or treating neurologic and psychiatric diseases may be facing now. We want to communicate the measures we have in place to deliver an uninterrupted supply of medicines, preserve the health of our communities, and support those who may be experiencing heightened anxiety or challenges during this time.
The Lundbeck supply chain remains intact and we have not experienced any supply disruptions. We are closely monitoring the integrity of the entire supply chain, and we are committed to doing all we can to anticipate and mitigate any potential issues with availability of our therapies.
Lundbeck conducts clinical studies at investigational sites across the globe. We are monitoring and evaluating the safety situation at each site, and we will adhere to local public health guidance in every case. We aim to respect the demands placed upon our healthcare institutions at this time, while maintaining responsible commitments to participants currently involved in our clinical trials and others worldwide who are depending on us to press forward in our work to advance treatments for brain diseases. This is a rapidly evolving situation, and we will continually evaluate the status of each study and site.
Acknowledging the incredible demands being placed right now on healthcare providers, and to do our part to limit spread of the virus, Lundbeck Canada employees are working remotely until the pandemic is under control and it is appropriate to return to normal activities. Our sales force will utilize technology to remain in contact with healthcare providers and will be available as usual to answer questions and provide information and resources about our medicines.
This is an extraordinary time in history, and we know that many amongst us are experiencing heightened anxiety and may have concerns about their own or a loved one’s well-being. At Lundbeck, we strive to provide meaningful support to people impacted by brain diseases. We encourage you to reach out to your local mental health associations for support and guidance during this time.We will continue to monitor the COVID-19 situation and update our practices and actions as necessary. But be assured that our commitment to supporting people impacted by brain diseases will continue uninterrupted. At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. While the current situation is causing disruption in many aspects of our normal lives, we remain fully focused on making a difference, one person at a time. We’d also like to express our sincerest gratitude to the health care workers who are working on the frontlines to provide care to patients during the pandemic. Please click below to hear a brief message from Lundbeck’s President and CEO, Dr. Deborah Dunsire.
We strive to improve the lives of Canadians with brain diseases.
A specialized biopharmaceutical company focused exclusively on brain diseases.
Take your next career step with Lundbeck.